ArticleNature communications2022
How Carvedilol activates β
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Self-Nanoemulsifying Drug Delivery Systems for Cardiovascular Therapeutics: Formulation Strategies, Pharmacokinetic Enhancement and Precision-Oriented Translation.Journal of cardiovascular translational research · 2026Review
- Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.The American journal of psychiatry · 2026Review
- Kinetic model of partial agonism reveals cellular basis of ligand efficacy.The Journal of biological chemistry · 2026Article
- Biased signaling of β2-adrenergic receptor in physiological and pathological states.Cellular & molecular biology letters · 2026Review
- Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives.Biomedicines · 2026Review
- Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats.JHEP reports : innovation in hepatology · 2026Article
- Finn Waagstein and the paradigm shift in the treatment of heart failure with β-adrenergic receptor antagonists ('β-blockers').Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Exercise-induced βBrain, behavior, and immunity · 2025Article
- A Fluorescent Probe Enables the Discovery of Improved Antagonists Targeting the Intracellular Allosteric Site of the Chemokine Receptor CCR7.Journal of medicinal chemistry · 2025Article
- Association of Circulating Phenylacetylglutamine With Multi-Vessel Coronary Disease Severity and Outcomes in ST-Segment-Elevation Myocardial Infarction.Journal of the American Heart Association · 2025Article
- A molecular mechanism to diversify CaNature communications · 2024Article
- G Protein-Coupled Receptors: A Century of Research and Discovery.Circulation research · 2024Review
- Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders.Handbook of experimental pharmacology · 2024Review
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Structures of Adrenoceptors.Handbook of experimental pharmacology · 2024Review
- How carvedilol does not activate βNature communications · 2023Article
- Reply to: How carvedilol does not activate βNature communications · 2023Article
- Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation.Bioscience reports · 2023Article
- Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.International journal of molecular sciences · 2023Review
- Detecting and measuring of GPCR signaling - comparison of human induced pluripotent stem cells and immortal cell lines.Frontiers in endocrinology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
30 authors at 9 institutions in 5 countries.
Tobias BenkelMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.ORCID http://orcid.org/0000-0001-8701-2706
Mirjam ZimmermannInterAx Biotech AG, 5234, Villigen, Switzerland.
Julian ZeinerMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.
Sergi BravoMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.ORCID http://orcid.org/0000-0001-5541-2860
Nicole MertenMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.ORCID http://orcid.org/0000-0002-8487-6805
Victor Jun Yu LimDepartment of Pharmaceutical Chemistry, Philipps-University of Marburg, 35032, Marburg, Germany.
Edda Sofie Fabienne MattheesInstitute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University of Jena, 07745, Jena, Germany.ORCID http://orcid.org/0000-0002-7760-5900
Julia DrubeInstitute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University of Jena, 07745, Jena, Germany.ORCID http://orcid.org/0000-0001-6188-2279
Elke Miess-TannebergInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University of Jena, 07747, Jena, Germany.
Daniela MalanInstitute of Physiology I, Medical Faculty, University of Bonn, 53115, Bonn, Germany.
Martyna SzpakowskaDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH), L-4354, Esch-sur-Alzette, Luxembourg.ORCID http://orcid.org/0000-0002-5659-8377
Stefania MonteleoneDepartment of Pharmaceutical Chemistry, Philipps-University of Marburg, 35032, Marburg, Germany.
Jak GrimesInstitute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, B15 2TT, UK.
Zsombor KoszegiInstitute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0003-2192-0159
Yann LanoiseléeInstitute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, B15 2TT, UK.
Shannon O'BrienInstitute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0003-3265-6998
Nikoleta PavlakiInstitute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Nadine DobbersteinInterAx Biotech AG, 5234, Villigen, Switzerland.
Asuka InoueGraduate School of Pharmaceutical Science, Tohoku University, Sendai, 980-8578, Japan.ORCID http://orcid.org/0000-0003-0805-4049
Viacheslav NikolaevInstitute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.ORCID http://orcid.org/0000-0002-7529-5179
Davide CalebiroInstitute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0002-3811-1553
Andy ChevignéDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH), L-4354, Esch-sur-Alzette, Luxembourg.ORCID http://orcid.org/0000-0003-4768-6743
Philipp SasseInstitute of Physiology I, Medical Faculty, University of Bonn, 53115, Bonn, Germany.ORCID http://orcid.org/0000-0002-8502-9472
Stefan SchulzInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University of Jena, 07747, Jena, Germany.
Carsten HoffmannInstitute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University of Jena, 07745, Jena, Germany.ORCID http://orcid.org/0000-0003-0884-9300
Peter KolbDepartment of Pharmaceutical Chemistry, Philipps-University of Marburg, 35032, Marburg, Germany.ORCID http://orcid.org/0000-0003-4089-614X
Maria WaldhoerInterAx Biotech AG, 5234, Villigen, Switzerland.
Katharina SimonMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.
Jesus GomezaMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.
Evi KostenisMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany. kostenis@uni-bonn.de.ORCID http://orcid.org/0000-0001-8284-5514
University of Bonn · DEUniversity of Birmingham · GBJena University Hospital · DEPhilipps University of Marburg · DELuxembourg Institute of Health · LUUniversität Hamburg · DEPA Consulting Group · GBResearch & Diagnostic Antibodies (United States) · USTohoku University · JP
Funding
Wellcome Trust 212313/Z/18/Z
Abstract
Carvedilol is among the most effective β-blockers for improving survival after myocardial infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of β
Indexed as
Adrenergic beta-AntagonistsMyocardial InfarctionCarvedilolHumansReceptors, Adrenergic, beta-2Adrenergic beta-AntagonistsCarvedilolReceptors, Adrenergic, beta-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.